,
Potard, Valérie http://orcid.org/0000-0003-3682-8347
Goujard, Cécile
Valantin, Marc Antoine
Lacombe, Jean Marc
Lahoulou, Rima
Chéret, Arnaud
Girard, Pierre Marie
Costagliola, Dominique
Funding for this research was provided by:
Janssen
Article History
Received: 4 July 2017
Accepted: 2 July 2018
First Online: 11 July 2018
Ethics approval and consent to participate
: The FHDH project was approved by the French data protection authority (CNIL) on 27 November 1991 (Journal Officiel, 17 January 1992). All individuals provided written informed consent to participate in the study. Data submitted by the participating centres to the statistical data centre that coordinates the cohort, are anonymized on the basis of the patient’s last name, first name, and day and month of birth.
: Not applicable.
: VP and JML reported no conflict of interest; CG has received travel/accommodations/meeting expenses from MSD, ViiV, Janssen-Cilag; MAV has received honoraria for travel/accommodations/meeting expenses from Janssen-Cilag, Gilead Science, ViiV, Bristol-Myers Squibb, and Merck-Sharp & Dohme-Chibret; RL was employee of Janssen; AC is employee of Janssen; PMG has received institutional grant from Gilead and Roche, payments for board membership from MSD, Janssen, BMS and Gilead, and for lectures from BMS, Janssen and Viiv HealthCare; DC was a member of the French Gilead HIV board up to 2015. In the past 3 years she has given lectures for Janssen-Cilag, Merck-Sharp & Dohme-Chibret, ViiV and received travel/accommodations/meeting expenses from Gilead, ViiV, Janssen-Cilag. She conducted post-marketing studies for Janssen-Cilag, Merck-Sharp & Dohme-Chibret and ViiV. She is currently a consultant for Innavirvax.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.